Post-transplant lymphoproliferative disorder presenting with skin ulceration in a renal transplant recipient who achieved sustained remission with rituximab therapy: A case report.
نویسندگان
چکیده
Post-transplant lymphoproliferative disorder (PTLD) is associated with a variety of clinical presentations, but rarely involves the skin. We herein report a case of PTLD presenting with skin ulceration in a renal transplant recipient. A biopsy of the ulcer confirmed the diagnosis of diffuse large B-cell lymphoma. The patient was initially treated with immunosuppression reduction, but the skin ulcer persisted. He was then treated with two courses of chemotherapy, but his condition was complicated with cryptococcal infection. Antifungal agents were administered to control the fungal infection. The patient later developed lymphoma recurrence and was successfully treated with single-agent rituximab. The patient remains well 6 years after treatment, with no evidence of disease relapse. Therefore, PTLD may manifest as skin lesions and physicians must be aware of this rare presentation.
منابع مشابه
Post-transplant lymphoproliferative disorder presenting as a tumor adjacent to the renal allograft: A case report and review of the literature
Post-transplant lymphoproliferative disorder (PTLD) is a potentially fatal complication of solid organ transplantation. The current report presents the case of a 42-year-old male who developed PTLD within the first year following renal transplantation. The disorder manifested as a tumor adjacent to the lower pole of the renal allograft and resulted in urinary obstruction. Durable complete remis...
متن کاملRituximab Is Indispensable for Pediatric Heart Transplant Recipients Developing Post transplant Lymphoproliferative Disorders
Abstract Rituximab, an anti-CD20 agent, has been suggested as an effective strategy to deal with post transplant lymphoproliferative disorders (PTLD). In the current study, we aim to evaluate the efficacy of rituximab therapy in heart transplant population developing PTLD. A comprehensive search of the literature was performed to gather the available data on lymphoproliferative disorders oc...
متن کاملRituximab therapy in early recurrent focal segmental sclerosis after renal transplantation.
Kidney transplants may be lost due to recurrence of the primary disease. In glomerulonephritis, all kinds taken together, 3% of the patients lose their grafts due to recurrence [1]. If, however, a first kidney graft has been lost from recurrence, the rate of failure caused by recurrence in subsequent grafts is ∼48% [1]. Focal segmental glomerulosclerosis (FSGS) in a young patient is associated ...
متن کاملRelationship between post-transplant lymphoproliferative disorder and Anti-Thymocyte Globulin or Anti-Lymphocyte Globulin
Abstract Background: Lymphoproliferative disorders are among the most serious and potentially fatal complications of chronic immunosuppression in kidney transplant recipients. The principle risk factors for development of PTLD are the degree of overall immunosuppression and the EBV serostatus of the recipient. In this study, the risk of PTLD in kidney transplant recipients who received Anti- L...
متن کاملPost-transplant lymphoproliferative disorder: case report and review of susceptibility to EBV in the Scottish adult renal transplant pool
We report a case of high-grade non-Hodgkin's lymphoma following Epstein-Barr virus (EBV) infection in a 38-year-old renal transplant recipient who was successfully treated with rituximab and remains alive 6 years later with reasonable graft function. We subsequently undertook a survey showing that 1.8% of the Scottish adult transplant pool are susceptible to EBV infection. Though a vaccine for ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Molecular and clinical oncology
دوره 5 5 شماره
صفحات -
تاریخ انتشار 2016